| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 |
Form 4: Jampa Raj, Chief Technology Officer
Granted 58,560 Time-Based Stock Option |
| 09 Nov 2026 |
Form 4: Sikri Vishal, EVP, Commercial
Granted 53,236 Time-Based Stock Option |
| 09 Nov 2026 |
Form 4: Solaiman Shereen, Chief People Officer
Granted 83,049 Time-Based Stock Option |
| 09 Nov 2026 |
Form 4: Fox Jennifer Lynne, Chief Legal & Corp Strategy
Granted 139,267 Time-Based Stock Option |
| 09 Nov 2026 |
Form 4: Muzzey Dale, Chief Scientific Officer
Granted 92,632 Time-Based Stock Option |
| 09 Nov 2026 |
Form 4: Verratti Mark, Chief Operating Officer
Granted 146,933 Time-Based Stock Option |
| 09 Nov 2026 |
Form 4: Wheeler Benjamin Richard, Chief Financial Officer
Granted 121,379 Time-Based Stock Option |
| 09 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
2026 Employee, Director and Consultant Equity Incentive Plan |
| 06 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Other Events
On November 2, 2026, Myriad Genetics, Inc. (the “Company”) detected unauthorized access within its information technology network environment. Upon discovery, the Company promptly initiated its incident response procedures to contain the... |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
SALT LAKE CITY, November 4, 2026 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2026, and raised the mi... |
| 02 Nov 2026 |
Form 4: Fox Jennifer Lynne, Chief Legal & Corp Strategy
Received 39,370 shares as a grant or award |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 20 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
______________________________________________________________________________ |
| 09 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Separation Agreement and Release of Claims (“Agreement”) is entered into by and between Myriad Genetics, Inc. (together with its subsidiaries, affiliates, successors and assigns, the “Company”) and Brian Donnelly (“Executive” and to... |
| 22 Sep 2026 |
Form 4: Wheeler Benjamin Richard, Chief Financial Officer
Gave up 2,555 shares to cover exercise price or tax ($10.2K) |
| 18 Sep 2026 |
Form 4: Donnelly Brian J, Chief Commercial Officer
Holds 573,363 shares of Common Stock |
| 17 Sep 2026 |
Form 4: Sikri Vishal, EVP, Commercial
Received 257,731 shares as a grant or award |
| 17 Sep 2026 |
Form 3: Sikri Vishal, EVP, Commercial
Holds 93,493 shares of Common Stock |
Loading...